[go: up one dir, main page]

WO1999023092A3 - 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them - Google Patents

3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them Download PDF

Info

Publication number
WO1999023092A3
WO1999023092A3 PCT/US1998/022936 US9822936W WO9923092A3 WO 1999023092 A3 WO1999023092 A3 WO 1999023092A3 US 9822936 W US9822936 W US 9822936W WO 9923092 A3 WO9923092 A3 WO 9923092A3
Authority
WO
WIPO (PCT)
Prior art keywords
zines
benzoxa
aminoalkylamino
thia
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/022936
Other languages
French (fr)
Other versions
WO1999023092A2 (en
Inventor
Xiao-Shu He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Priority to CA002307905A priority Critical patent/CA2307905A1/en
Priority to AU12863/99A priority patent/AU1286399A/en
Priority to EP98956310A priority patent/EP1027347A2/en
Priority to JP2000518963A priority patent/JP2001521935A/en
Publication of WO1999023092A2 publication Critical patent/WO1999023092A2/en
Publication of WO1999023092A3 publication Critical patent/WO1999023092A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Disclosed are compounds of formula (I) or the pharmaceutically acceptable acid addition salts thereof, wherein: Ar represents aryl or heteroaryl; R1 and R2 are the same or different and represent organic or inorganic substituents; R5 is hydrogen or C1-C6 alkyl; W represents CH or nitrogen; X is oxygen or sulfur; and A represents an alkylene group, which compounds bind selectively with high affinity to the dopamine D4 receptor subtype and are therefore of use in treatment of various neuropsychological disorders.
PCT/US1998/022936 1997-10-31 1998-10-28 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them Ceased WO1999023092A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002307905A CA2307905A1 (en) 1997-10-31 1998-10-28 3-aminoalkylamino-2h-1,4-benzoxazines and 3-aminoalkylamino- 2h-1,4-benzothiazines: dopamine receptor subtype specific ligands
AU12863/99A AU1286399A (en) 1997-10-31 1998-10-28 3-aminoalkylamino- 2h-1,4-benzoxazines and 3-aminoalkylamino- 2h-1,4-benzothiazines: dopamine receptor subtype specific ligands
EP98956310A EP1027347A2 (en) 1997-10-31 1998-10-28 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them
JP2000518963A JP2001521935A (en) 1997-10-31 1998-10-28 3-aminoalkylamino-2H-1,4-benzoxyazine and 3-aminoalkylamino-2H-1,4-benzothiazine: ligands specific to dopamine receptor subtypes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96202297A 1997-10-31 1997-10-31
US08/962,022 1997-10-31

Publications (2)

Publication Number Publication Date
WO1999023092A2 WO1999023092A2 (en) 1999-05-14
WO1999023092A3 true WO1999023092A3 (en) 1999-08-05

Family

ID=25505330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/022936 Ceased WO1999023092A2 (en) 1997-10-31 1998-10-28 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them

Country Status (5)

Country Link
EP (1) EP1027347A2 (en)
JP (1) JP2001521935A (en)
AU (1) AU1286399A (en)
CA (1) CA2307905A1 (en)
WO (1) WO1999023092A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100255A (en) * 1998-10-28 2000-08-08 Neurogen Corporation 3-aminoalkylamino-2H-1,4-benzoxazines and 3-aminoalkylamino-2H-1,4-benzothiazines: dopamine receptor subtype specific ligands
CN1293669A (en) * 1998-02-26 2001-05-02 纽罗根公司 Benzylpiperazingl-and benzylipeeridinyl ethanone derivatives, their preparation method and their use as dopamine D receptor antagonists
US6084098A (en) 1999-02-26 2000-07-04 Neurogen Corporation Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
WO2000018767A2 (en) * 1998-09-30 2000-04-06 Neurogen Corporation 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
US6284759B1 (en) 1998-09-30 2001-09-04 Neurogen Corporation 2-piperazinoalkylaminobenzo-azole derivatives: dopamine receptor subtype specific ligands
DE19941115A1 (en) * 1999-08-25 2001-03-01 Schering Ag New benzoxazine and bezothiazine derivatives and their use in drugs
EP1177792A3 (en) 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
US8411271B2 (en) 2005-12-28 2013-04-02 Nikon Corporation Pattern forming method, pattern forming apparatus, and device manufacturing method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0186310A1 (en) * 1984-11-28 1986-07-02 Takeda Chemical Industries, Ltd. 1,4-Benzothiazine Derivatives, their production and use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0186310A1 (en) * 1984-11-28 1986-07-02 Takeda Chemical Industries, Ltd. 1,4-Benzothiazine Derivatives, their production and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIAO S. H.: "A NEW SERIES OF SELECTIVE DOPAMINE D4 LIGANDS:", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 18, 1997, GB, pages 2399 - 2402, XP004136452 *

Also Published As

Publication number Publication date
EP1027347A2 (en) 2000-08-16
AU1286399A (en) 1999-05-24
CA2307905A1 (en) 1999-05-14
JP2001521935A (en) 2001-11-13
WO1999023092A2 (en) 1999-05-14

Similar Documents

Publication Publication Date Title
MXPA05003193A (en) Novel adenine compound and use thereof.
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
CA2318349A1 (en) Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
AU8794291A (en) New oxazolopyridine derivatives, processes for preparing these and pharmaceutical compositions containing them
TW200510381A (en) Novel 2-pyridinecarboxamide derivatives
IL154893A0 (en) Aliphatic nitrogen-containing cyclic compounds, methods for the preparation thereof and pharmaceutical compositions containing the same
HK1046688A1 (en) Quinazoline compounds and pharmaceutical compositions containing them
CA2247443A1 (en) Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma
HUP0004529A2 (en) Sulfonilated dipeptide-compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
LU92033I2 (en) Plerixafor and its pharmaceutically acceptable derivatives (MOZOBIL®)
GB9803226D0 (en) Chemical compounds
CA2203237A1 (en) Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
NZ330973A (en) Azolobenzazepine derivatives as neurologically active agents
IL145759A0 (en) Amine derivatives and pharmaceutical compositions containing the same
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
EP1719761A4 (en) Novel heterocyclic compound
DE3876813D1 (en) 3 (2H) PYRIDAZINONE, METHOD FOR THE PRODUCTION THEREOF AND ITS CONTAINER AGAINST SRS-A.
WO2000018769A3 (en) INDOLO[2,1-b]QUINAZOLE-6,12-DIONE ANTIMALARIAL COMPOUNDS AND METHODS OF TREATING MALARIA THEREWITH
NO20003773L (en) Cyclobutene derivatives, their preparation and their therapeutic uses
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
WO1999023092A3 (en) 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them
WO2002007677A3 (en) Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
EP1550651A4 (en) GLYCEROL DERIVATIVE
CA2247946A1 (en) Anticachectic composition
EP1142883A4 (en) Novel heterocyclic compounds and drug compositions containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/A/2000/003954

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2307905

Country of ref document: CA

Ref document number: 2307905

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 518963

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998956310

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 98812701.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1998956310

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998956310

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642